Women who have completed treatment for stage II, III or IV ovarian, fallopian tube or primary peritoneal cancer and are cancer free will be randomized to either Group 1 (diet and physical activity intervention group) or Group 2 (the usual diet and physical activity group). Group 1 Intervention will include regularly scheduled lifestyle intervention coaching sessions that will be conducted over the telephone and increased physical activity. Patients will be asked to complete daily lifestyle journal that will track daily fat grams and steps. Group 2 will continue with ususal diet and physical activity and will participate in coaching phone calls. Participants will be asked to complete Patient Questionnaires. If participants consent to optional blood submission study, blood samples for research will be drawn at baseline, 3, 6,12 and 24 months from study entry. Participation will last for 24 months.
This is a Phase II study for women diagnosed with pelvic-only and or vaginal recurrence of endometrial cancer following complete hysterectomy and bilateral salpingo-oophorectomy at the time of initial diagnosis . Patients will be randomized to receive external pelvic radiation for approximately 5 weeks followed by brachytherapy OR external pelvic radiation for approximately 5 weeks plus weekly chemotherapy with cisplatin followed by brachytherapy. The study is designed as a screening study to estimate the benefit on progression-free survival of the addition of cisplatin to external pelvic irradiation, overall survival, side effects and evaluate factors at study entry and from original hysterectomy as potential prognostic factors.